title: Prolactinoma and pregnancy - a series of cases including pituitary apoplexy.
abstract: The objective of this article is to evaluate the impact of pregnancy in women with prolactinoma, the possible consequences of therapy maintenance/discontinuation during pregnancy and to assess the type of delivery and maternal-foetal obstetrical outcome. A retrospective study of all pregnant women with prolactinoma in our Centre between 2006 and 2014 was made. We had 35 cases of pregnant women with prolactinoma, two of which had an episode of pituitary apoplexy during the second trimester. At the time of conception, most women were being treated with 5 mg bromocriptine. The majority of women had suspended medication in the 8th week of gestation. Caesarean rate was 48.6%. The maternal foetal outcome was favourable in all cases.
authors.affiliation: a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
authors.forename: Ana
authors.initials: A
authors.lastname: Galvão
authors.affiliation: a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
authors.forename: Daniela
authors.initials: D
authors.lastname: Gonçalves
authors.affiliation: a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
authors.forename: Marta
authors.initials: M
authors.lastname: Moreira
authors.affiliation: a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
authors.forename: Gonçalo
authors.initials: G
authors.lastname: Inocêncio
authors.affiliation: a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
authors.forename: Clara
authors.initials: C
authors.lastname: Silva
authors.affiliation: a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
authors.forename: Jorge
authors.initials: J
authors.lastname: Braga
mesh_terms: D000328:Adult; D001942:Breast Feeding / Q000009:adverse effects / Q000706:statistics & numerical data; D001971:Bromocriptine / Q000008:administration & dosage*; D002585:Cesarean Section / Q000706:statistics & numerical data; D018491:Dopamine Agonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000209:etiology*; D007231:Infant, Newborn; D008279:Magnetic Resonance Imaging; D010899:Pituitary Apoplexy / Q000150:complications; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy; D015175:Prolactinoma / Q000150:complications* / Q000188:drug therapy; D012189:Retrospective Studies; D028761:Withholding Treatment
chemical_list: D018491:Dopamine Agonists; D001971:Bromocriptine
keywords: Prolactinoma; caesarean section; maternal outcome; perinatal outcome; pituitary apoplexy; pregnancy